Impact of Dietary Phosphate Excess on Exercise Capacity and Visceral Adiposity
University of Texas Southwestern Medical Center
124 participants
Sep 14, 2022
INTERVENTIONAL
Conditions
Summary
Studies in mice demonstrated that dietary phosphate (Pi) loading that mimic the level of US adult consumption leads to reduced spontaneous locomotor activity, exercise capacity, and reduced resting metabolic rate when in normal mice by impairing skeletal muscle mitochondrial function and fat oxidation. However, relevance of this findings in humans remains unknown.
Eligibility
Inclusion Criteria1
- The randomized crossover trial will be performed in on otherwise healthy subjects without diabetes mellitus, chronic kidney disease (CKD), preexisting cardiovascular disease or treatment with any vasoactive agent that might alter cardiovascular responses to exercise.
Exclusion Criteria4
- history of cardiopulmonary disease or chronic kidney disease,
- treatment with antihypertensive medications,
- estimated glomerular filtration rate (eGFR) \< 60 mL/min/1.73m2, (4) diabetes mellitus or other systemic illness,
- (5) pregnancy, (6) hypersensitivity to sodium phosphate, (7) any history of substance abuse or current cigarette use, (8) any history of psychiatric illness, (9) history of active malignancy, (10) serum phosphorus \< 2.4 or \> 4.5 mg/dL.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Sodium Phosphate 2 capsules daily (containing a total of 500 mg of Pi, 372mg of sodium)
Sodium Chloride 2 capsules daily (NaCl, containing a total of 372mg of sodium)
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05147909